Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

5.41
+0.28005.46%
Post-market: 5.39-0.0200-0.37%19:54 EDT
Volume:27.55M
Turnover:147.00M
Market Cap:2.23B
PE:-4.94
High:5.63
Open:5.02
Low:5.01
Close:5.13
52wk High:5.63
52wk Low:1.64
Shares:411.96M
Float Shares:339.00M
Volume Ratio:1.15
T/O Rate:8.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0941
EPS(LYR):-1.0941
ROE:-55.50%
ROA:-27.30%
PB:3.19
PE(LYR):-4.94

Loading ...

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jan 28

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 17

Iovance Biotherapeutics (IOVA) Receives a Buy from Wells Fargo

TIPRANKS
·
Jan 16

Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone

Simply Wall St.
·
Jan 11

Iovance Biotherapeutics Showcases TIL Therapy Advances and Melanoma Treatment Outcomes in New Corporate Presentation

Reuters
·
Jan 09

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 20, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

Iovance Biotherapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Nov 24, 2025

Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays

TIPRANKS
·
Nov 24, 2025

Iovance Biotherapeutics Grants Stock Options to New Employees Under Amended Inducement Plan

Reuters
·
Nov 22, 2025

Stock Track | Iovance Biotherapeutics Soars 5.65% Pre-Market Despite Mixed Goldman Sachs Report

Stock Track
·
Nov 10, 2025

Iovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs

TIPRANKS
·
Nov 10, 2025

Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Plunges 5.19% Pre-market Following Chardan's Price Target Cut

Stock Track
·
Nov 07, 2025

Chardan Cuts Price Target on Iovance Biotherapeutics to $17 From $20, Keeps Buy Rating

MT Newswires Live
·
Nov 07, 2025

Stock Track | Iovance Biotherapeutics Soars 6.93% on Strong Q3 Results and Revenue Growth

Stock Track
·
Nov 07, 2025

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 07, 2025

Iovance Biotherapeutics Up Over 35%, on Pace for Largest Percent Increase Since May 2019 -- Data Talk

Dow Jones
·
Nov 07, 2025

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 07, 2025